According to the study it was found that GlaxoSmithKline Plc which funded the research in the production of vaccine against middle-ear infections in infants said that the vaccine was viable. GlaxoSmithKline Plc is the world's second-biggest drug maker.
Roman Prymula, who led the study at the Czech Republic's University of Defense, said that further tests are necessary before the vaccine hits the market.
The vaccine contained proteins from 11 strains of a bacterium that causes middle ear infections. The study results were up in the journal Lancet.
The study was conducted on a group of 4,698 infants aged three months to 15 months. Some of the infants received the vaccine and others served as the control group.
Follow up studies were done on these children and the researchers examined these children around the time of their third birthdays.
The results were astonishing they found that 333 children who received the vaccine suffered from middle ear infection, compared with 499 in the control group.
Statistics show that about 20 million U.S. children are treated for middle ear infections each year.
In conclusion the researchers say that if the vaccine hits the market then it would reduce the number of infants suffering from middle-ear infections.